139 related articles for article (PubMed ID: 8012775)
1. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression.
Gardiner RA; Walsh MD; Allen V; Rahman S; Samaratunga ML; Seymour GJ; Lavin MF
Br J Urol; 1994 May; 73(5):526-32. PubMed ID: 8012775
[TBL] [Abstract][Full Text] [Related]
2. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.
Thomas DJ; Robinson MC; Charlton R; Wilkinson S; Shenton BK; Neal DE
Br J Urol; 1994 May; 73(5):533-7. PubMed ID: 8012776
[TBL] [Abstract][Full Text] [Related]
3. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder.
Toktaş G; Türkeri LN; Unlüer E; Atuğ F; Murat C; Ozveren B; Calişkan M; Akdaş A
Int Urol Nephrol; 1999; 31(4):437-41. PubMed ID: 10668937
[TBL] [Abstract][Full Text] [Related]
5. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
Serth J; Kuczyk MA; Bokemeyer C; Hervatin C; Nafe R; Tan HK; Jonas U
Br J Cancer; 1995 Jan; 71(1):201-5. PubMed ID: 7819040
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
7. p53 overexpression as a prognostic factor for advanced stage bladder cancer.
Kuczyk MA; Bokemeyer C; Serth J; Hervatin C; Oelke M; Höfner K; Tan HK; Jonas U
Eur J Cancer; 1995 Dec; 31A(13-14):2243-7. PubMed ID: 8652250
[TBL] [Abstract][Full Text] [Related]
8. [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].
Rodríguez Alonso A; Pita Fernández S; González-Carreró J; Nogueira March JL
Actas Urol Esp; 2003 Feb; 27(2):132-41. PubMed ID: 12731328
[TBL] [Abstract][Full Text] [Related]
9. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.
Tokunaga H; Shariat SF; Green AE; Brown RM; Zhou JH; Benedict WF; Lerner SP
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):16-22. PubMed ID: 11516846
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
12. Biological characterisation of superficial bladder cancer by bivariate cytokeratin 7/DNA analysis, flow cytometric assessment of MIB- 1, and an immunohistochemical study.
Leonardi E; Dalla Palma P; Reich A; Caffo O; Luciani L
Anal Cell Pathol; 2000; 21(1):21-33. PubMed ID: 11254222
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
[TBL] [Abstract][Full Text] [Related]
14. [New quantitative method for determining p53 protein in bladder carcinomas].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Chicharro Almarza J; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1997 May; 50(4):347-53. PubMed ID: 9313043
[TBL] [Abstract][Full Text] [Related]
15. Expression of pS2 protein in transitional cell bladder tumours.
Lipponen PK; Eskelinen MJ
J Pathol; 1994 Aug; 173(4):327-32. PubMed ID: 7965392
[TBL] [Abstract][Full Text] [Related]
16. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.
Hitchings AW; Kumar M; Jordan S; Nargund V; Martin J; Berney DM
Br J Cancer; 2004 Aug; 91(3):552-7. PubMed ID: 15226775
[TBL] [Abstract][Full Text] [Related]
17. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
18. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor.
Takagi Y; Takashi M; Koshikawa T; Sakata T; Ohshima S
Int J Urol; 2000 Oct; 7(10):366-72. PubMed ID: 11144504
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of p53 in superficially infiltrating transitional cell carcinoma.
Vatne V; Maartmann-Moe H; Hoestmark J
Scand J Urol Nephrol; 1995 Dec; 29(4):491-5. PubMed ID: 8719368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
